bioRxivCancer BiologyPreprint
Antigenic cancer persister cells survive direct T cell attack
Michael WangiD, Brandon E. Mauch, August Finley WilliamsiD, Tania Barazande-Pour, Filipe Araujo HoffmanniD, Sophie H. Harris, Cooper P. LathropiD, Claire E. Turkal, Bryan S. YungiD, Michelle H. Paw, David A. G. GervasioiD, Tiffany TraniD, Anna E. StuhlfireiD, Theresa W. GuoiD, Gregory A. DanielsiD, Soo Jean ParkiD, Jorge Silvio GutkindiD, Matthew J. HangaueriD
Abstract
Drug-tolerant persister cancer cells were first reported fifteen years ago as a quiescent, reversible cell state which tolerates unattenuated cytotoxic drug stress. It remains unknown whether a similar phenomenon contributes to immune evasion. Here we report a persister state which survives weeks of direct cytotoxic T lymphocyte (CTL) attack. In contrast to previously known immune evasion mechanisms that avoid immune attack, antigenic persister cells robustly activate CTLs which deliver Granzyme B, secrete IFN{gamma}, and induce tryptophan starvation resulting in apoptosis initiation. Instead of dying, persister cells paradoxically leverage apoptotic caspase activity to avoid inflammatory death. Furthermore, persister cells acquire mutations and epigenetic changes which enable outgrowth of CTL-resistant cells. Persister cell features are enriched in inflamed tumors which regressed during immunotherapy in vivo and in surgically resected human melanoma tissue under immune stress ex vivo. These findings reveal a persister cell state which is a barrier to immune-mediated tumor clearance. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=102 SRC="FIGDIR/small/643359v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@1ca8905org.highwire.dtl.DTLVardef@1e9b584org.highwire.dtl.DTLVardef@8bf43eorg.highwire.dtl.DTLVardef@504918_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: development & morphogenesis
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 3
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms
Maria Davern, Cole J. Turner, … Anthony G. Letai·Cell Death and DifferentiationPeer-reviewed·Dec 26, 2025
- Transient cell-in-cell formation underlies tumor resistance to immunotherapy
A. Gutwillig, N. Santana-Magal, … Y. Carmi·bioRxiv·Sep 10, 2020
- Induction of senescence renders cancer cells highly immunogenic
I. Marin, O. Boix, … M. Serrano·bioRxiv·Jun 5, 2022
- Persister cells and their effects on cancer stabilization therapy
Mohammadreza Satouri, Philipp M. Altrock, … Kateřina Staňková·bioRxiv·Oct 16, 2026
- Persister cancer cells are characterized by H4K20me3 heterochromatin that defines a low inflammatory profile
V. Ramponi, L. Richart, … M. Serrano·bioRxiv·Jan 26, 2024
- Identification of a shared persistence program in triple-negative breast cancer across treatments and patients
Léa Baudre, Grégoire Jouault, … Céline Vallot·bioRxiv·Mar 17, 2025